Dendreon Announces Plans to Make PROVENGE® Commercially Available in Europe Dendreon Corporation (NASDAQ: DNDN ) today announced that it plans to make PROVENGE® (autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or sipuleucel-T) available in Europe, beginning ...
March 3, 2014 - Benzinga via Yahoo! Finance
Ajith Kumar in Hindu The mesenchymal stem cells are separated from the mononuclear ones,said Dr. Kumar. "One in 300 mononuclear cells turns out to be a mesenchymal stem cell."